You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 258 No. 24, December 25, 1987 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Diagnostic and therapeutic technology assessment. Chorionic villus sampling


Chorionic villus sampling has a promising future as a means of early detection of fetal abnormalities. It has widespread application in Europe, and more than 6000 procedures have been performed in the United States. Universal acceptance of the procedure has been delayed because of uncertainties over the true fetal loss rate. Information available today indicates that the fetal loss rate should be in the same range as that for amniocentesis--approximately 1% or less. Confirmation of these estimates awaits release of the data from the large clinical trials currently under way. Modifications of the sampling technique are also under investigation. Transabdominal CVS can also be performed early in pregnancy (six to 15 weeks) with a fine-bore needle and cannula under ultrasonic guidance. It remains to be seen if this offers any advantages or incurs additional risks over transcervical CVS.





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.